tion, USP; AirFluSal Forspiro; Kerydin (tavaborole) topical solution, 5%; Vitaros (alprostadil); Dexmethylphenidate ER (Focalin XR); Tobramycin inhalation solution, USP (TOBI); Calcipotriene and betamethasone dipropionate ointment, (Taclonex, Leo Pharma); Adapalene gel (Differin, Galderma Laboratories); Lansoprazole capsules, amoxicillin capsules, USP, and clarithromycin tablets, USP (PREVPAC, Takeda Pharmaceuticals); Decitabine (Dacogen, Eisai); Escitalopram (Cipralex, Lundbeck); and Mometasone (Nasonex, Merck Sharp & Dohme). Sales and Marketing: Sandoz division sells a portfolio of generic pharmaceutical products to wholesalers, pharmacies, hospitals and other healthcare outlets. Significant Events The company discontinued the following businesses: Vaccines: Preventive human vaccines and the blood transfusion diagnostics unit, which was divested on January 9, 2014; and Consumer Health: OTC (OTC medicines) (following the January 1, 2015 completion of the divestment of Animal Health Division to Lilly, the Consumer Health segment consists only of the OTC Division). In March 2015, Novartis announced that it is stepping up its efforts to harness the body's immune system to combat cancer. The company has entered into a major multiyear alliance with Aduro Biotech that is focused on the discovery and development of next generation cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway and launched a new immuno-oncology research group led by renowned cancer vaccine expert Glenn Dranoff, MD. In July 2015, Aequus Pharmaceuticals Updates on Definitive Agreement to acquire TeOra Health LENGTH:Â 948 words Aequus Pharmaceuticals reported that it has entered into a definitive agreement to acquire TeOra Health as part of its growth strategy to build a commercial arm in Canada. In August 2015, Amgen announced neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. In October 2015, Sandoz, the generics division of Novartis, has stated its support for approval of the Trans-Pacific Partnership (TPP) trade agreement by Mexico. In November 2015, Thermo Fisher Scientific entered an agreement with Novartis and Pfizer to develop a next-generation sequencing-based (NGS) companion diagnostic (CDx) test. In November 2015, Thermo Fisher Scientific entered into a long-term agreement with Novartis and Pfizer to develop and commercialize a multi-marker, universal sequencing (NGS) oncology test that will serve as a companion diagnostic (CDx) for non-small cell lung cancer (NSCLC) across multiple drug development programs. History Novartis AG was founded in 1895.
novartis ag-sponsored adr (NVS:New York)
Phone: 41 61 324 11 11
|Allergan plc||$313.89 USD||0.00|
|Gilead Sciences Inc||$105.96 USD||0.00|
|Johnson & Johnson||$101.24 USD||-1.13|
|Nestle SA||SFr.76.35 CHF||-0.05|
|Pfizer Inc||$32.77 USD||-0.02|
|View Industry Companies|
Sponsored Financial Commentaries
To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.